Background. Sucroferric oxyhydroxide is a noncalcium, ironbased phosphate binder that demonstrated sustained serum phosphorus control, good tolerability and lower pill burden compared with sevelamer carbonate (sevelamer) in a Phase 3 study conducted in dialysis patients. This subanalysis examines the efficacy and tolerability of sucroferric oxyhydroxide and sevelamer in the peritoneal dialysis (PD) patient population. Methods. The initial study (NCT01324128) and its extension (NCT01464190) were multicenter, Phase 3, open-label, randomized (2:1), active-controlled trials comparing sucroferric oxyhydroxide (1.0-3.0 g/day) with sevelamer (2.4-14.4 g/day) in dialysis patients over 52 weeks in total. Results. In the overall study, 84/1055 (8.1%) patients received PD and were eligible for efficacy analysis (sucroferric oxyhydroxide, n ¼ 56; sevelamer, n ¼ 28). The two groups were broadly comparable to each other and to the overall study population. Serum phosphorus concentrations decreased comparably with both phosphate binders by week 12 (mean change from baseline À 0.6 mmol/L). Over 52 weeks, sucroferric oxyhydroxide effectively reduced serum phosphorus concentrations to a similar extent as sevelamer; 62.5% and 64.3% of patients, respectively, were below the Kidney Disease Outcomes Quality Initiative target range ( 1.78 mmol/L). This was achieved with a lower pill burden (3.4 6 1.3 versus 8.1 6 3.7 tablets/day) with sucroferric oxyhydroxide compared with sevelamer. Treatment adherence rates were 91.2% with sucroferric oxyhydroxide and 79.3% with sevelamer. The proportion of patients reporting at least one treatment-emergent adverse event was 86.0% with sucroferric oxyhydroxide and 93.1% with sevelamer. The most common adverse events with both treatments were gastrointestinal: diarrhea and discolored feces with sucroferric oxyhydroxide and nausea, vomiting and constipation with sevelamer.
I N T R O D U C T I O N
Hyperphosphatemia is a serious sequela of advanced chronic kidney disease (CKD) and is a risk factor for vascular calcification, cardiovascular events and death in both hemodialysis (HD) and peritoneal dialysis (PD) patients [1] [2] [3] [4] . Dietary restriction of phosphorus and dialysis alone do not provide sufficient control of phosphate levels. Therefore, the majority of patients with end-stage renal disease (ESRD) require treatment with oral phosphate binders [5] . Several phosphate binder options are available: among the most commonly used are calcium-based binders and the ion-exchange resin sevelamer [6, 7] . However, both types of agents have limitations, including a potential association with hypercalcemia and vascular calcification (calcium-based binders) [8, 9] and a high pill burden [7, [10] [11] [12] . These limitations are an important consideration, particularly for patients on PD, who are generally monitored in the clinic to a lesser extent than patients on HD and hence tend to have a greater need for a simple and reliable serum phosphate management strategy. PD patients account for $11% of the dialysis population globally [13] , so it is important to evaluate the efficacy and safety of new phosphate binders in this patient population.
Sucroferric oxyhydroxide is a noncalcium, iron-based phosphate binder with a high phosphorus-binding capacity and minimal iron release [14] . Sucroferric oxyhydroxide received approval for the treatment of hyperphosphatemia in dialysis patients based on data from a Phase 3 study and subsequent 28-week extension study that demonstrated sustained serum phosphorus control, good tolerability and lower pill burden compared with sevelamer carbonate [15, 16] . These sucroferric oxyhydroxide studies included a representative proportion ($8%) of patients receiving PD [15, 16] . This subanalysis of data from the initial Phase 3 and extension studies examines the 1-year efficacy, safety and tolerability of sucroferric oxyhydroxide versus sevelamer carbonate treatment in the PD patient population.
M A T E R I A L S A N D M E T H O D S

Study design
The initial Phase 3 study (NCT01324128) and its extension (NCT01464190) were multicenter, open-label, randomized, active-controlled trials. The design of the initial study and extension study have been described previously [15, 16] . In brief, following 2-4 weeks of washout, eligible HD and PD patients with serum phosphorus concentrations !1.94 mmol/L were randomized (2:1) to receive sucroferric oxyhydroxide [1.0-3.0 g/day (2-6 tablets/day); n ¼ 710] or sevelamer carbonate [2.4-14.4 g/day (3-18 tablets/day), starting dose 4.8 g/day (6 tablets/day); n ¼ 349] for a 12-week dose titration (weeks 1-12) followed by 12 weeks of maintenance (weeks 12-24). Doses of study treatments were titrated to achieve predefined serum phosphorus concentrations of 0.81-1.78 mmol/L (2.5-5.5 mg/dL).
Patients who met eligibility criteria were allowed to enter the extension study, continuing the same treatment and dosage they were receiving at the end of the initial study for a further 28 weeks.
Participants
The eligibility criteria for the initial Phase 3 study have been described previously [15] . In brief, eligible patients (!18 years of age) had a history of hyperphosphatemia and were receiving stable doses of one or more phosphate binders for !1 month prior to screening. All PD patients had to have received PD with a Kt/V (K ¼ dialyzer clearance of urea; t ¼ dialysis time; V ¼ subject's total body water) !1.7 within 3 months prior to screening.
Patients were ineligible if, at screening, they had intact parathyroid hormone (iPTH) levels >800 ng/L or serum ferritin >2000 ng/mL. PD patients with a history of peritonitis within the previous 3 months or with three or more episodes within the previous 12 months were also ineligible. Patients receiving noncalcium-based phosphate binders with hypercalcemia (total serum calcium >2.60 mmol/L) or patients with hypocalcemia (total serum calcium <1.9 mmol/L) at screening were also excluded.
Assessments, analysis sets and statistics
Details of efficacy and safety assessments during the initial study and extension have been described previously [15, 16] . Patients receiving PD had study visits every second week for the first 8 weeks, then every 4 weeks thereafter. All subsequent study visits were scheduled on the same day thereafter (61 day). Serum phosphorus was measured at a central laboratory. Adverse events (AEs) and concomitant medications were recorded from screening (informed consent signature) to the end of study participation.
Details of sample-size calculations and statistics have been described previously [15, 16] . Data collected from both the Phase 3 and extension studies were pooled for an integrated analysis of efficacy. Efficacy measures included change in serum phosphorus concentration from initial study baseline, pill burden (the number of tablets taken per day) and serum phosphorus control [defined by the proportion of patients with serum phosphorus within the Kidney Disease Outcomes Quality Initiative (KDOQI)-recommended target range (1.13-1.78 mmol/L; 3.5-5.5 mg/dL)] [17] .
The analysis sets evaluated in this post hoc analysis were as follows:
• Full analysis set (FAS): randomized patients who received one or more dose of study medication and had one or more postbaseline evaluable efficacy assessment during the initial Phase 3 study. • Safety set: randomized patients who took one or more dose of study medication during the Phase 3 study.
Safety end points included treatment-emergent AEs (TEAEs) and changes in iron-related parameters [ferritin, transferrin saturation (TSAT) and hemoglobin], bone markers and biochemical laboratory parameters [iPTH, fibroblast growth factor 23 (FGF-23) and C-reactive protein (CRP)]. Blood samples were analyzed using standardized methods at two central laboratories. Dialysis adequacy in PD patients was assessed by calculating total Kt/V values.
Treatment adherence was calculated based on the recorded number of tablets actually taken relative to the number of tablets expected to be taken (according to the dose over the subject's participation in the study) using dispensing and return records:
Treatment adherence ¼ Total number of tablets taken Number of tablets expected to be taken Â 100
All statistical tests on efficacy data were performed using two-sided tests at the 5% significance level. The analyses were conducted using SAS version 9.2 or later (SAS Institute, Cary, NC, USA). Differences in demographic and adherence data and AE reporting, as described in the Results section, were not tested for statistical significance and are descriptive only. Overall adherence was summarized using descriptive statistics. Patients were recorded as being adherent if their adherence was within 70-120% of the expected tablet intake.
R E S U L T S
Patient disposition and demographics
Of the 1055 patients included in the overall study population safety set (i.e. randomized to treatment and receiving at least one dose of study medication), 86 (8.2%) were receiving PD. A
total of 84 (8.1%) of these patients were eligible for efficacy analysis (FAS; n ¼ 56 in the sucroferric oxyhydroxide group, n ¼ 28 in the sevelamer carbonate group). The patient disposition is shown in Figure 1 . Overall, the majority of PD patients in both treatment groups ($83%) completed the initial 24-week Phase 3 study. Approximately two-thirds (66.7%) of PD patients in the sucroferric oxyhydroxide group and half (48.3%) in the sevelamer carbonate group completed 52 weeks of continuous treatment.
The demographic and clinical characteristics of PD patients enrolled in the initial Phase 3 study were broadly similar between the sucroferric oxyhydroxide and sevelamer carbonate treatment groups (Table 1) and to those reported for the overall study population [15] .
A greater proportion of patients in the sucroferric oxyhydroxide group had received intravenous (IV) iron within 2 weeks of study entry than in the sevelamer carbonate group (33.9 versus 10.7%; P ¼ 0.034).
All but one of the PD patients who participated in the study had previously received at least one phosphate binder therapy; 38.1% had previously been treated with either sevelamer carbonate or sevelamer hydrochloride (Table 1 ). 
Sucroferric oxyhydroxide was noninferior to sevelamer carbonate in terms of reducing serum phosphorus concentrations at week 12 in PD patients [mean change from baseline of À0.6 mmol/L in both treatment groups (P ¼ 0.53 for sucroferric oxyhydroxide versus sevelamer carbonate)]. Mean baseline serum phosphorus concentrations among patients in the sucroferric oxyhydroxide group were also significantly higher than in the sevelamer carbonate group (2.43 versus 2.17 mmol/L; P ¼ 0.036). Over 1 year of treatment, sucroferric oxyhydroxide effectively reduced serum phosphorus concentrations to a similar extent as sevelamer carbonate ( Figure 2 ).
Mean serum phosphorus concentrations remained below the upper limit of the KDOQI target range ( 1.78 mmol/L) for both treatment groups from week 24 until the end of the study (week 52). A similar proportion of patients in the sucroferric oxyhydroxide and sevelamer carbonate groups had levels below the KDOQI upper limit for serum phosphorus ( 1.78 mmol/L) at week 24 [57.1 (n ¼ 32) versus 60.7% (n ¼ 17), respectively] and week 52 [62.5 (n ¼ 35) versus 64.3% (n ¼ 18)].
Pill burden and adherence
Serum phosphorus control was achieved with a lower pill burden in patients receiving sucroferric oxyhydroxide than in those receiving sevelamer carbonate (safety set: 3.4 6 1.3 sucroferric oxyhydroxide tablets/day versus 8.1 6 3.7 sevelamer carbonate tablets/day). Overall, the proportion of PD patients adherent at the 70-120% level was higher among PD patients 
Mineral and bone metabolism parameters
Changes in bone parameters during the initial Phase 3 study and extension study are summarized in Table 2 . Mean iPTH levels in PD patients were high at baseline (week 0) and decreased slightly from baseline to week 24 in patients receiving sevelamer carbonate, but remained stable in the sucroferric oxyhydroxide group (Table 2) . However, this difference between the treatment groups was not statistically significant; by week 52 the mean serum iPTH was similar to baseline levels in both treatment groups. Serum FGF-23 levels decreased over 1 year across both treatment groups. Total serum calcium concentrations remained stable in both groups for the duration of the study.
The mean serum concentrations of 25-hydroxyvitamin D decreased from baseline to week 24 in both treatment groups, but returned to baseline levels by the end of the study (week 52). The mean serum concentrations of 1,25-dihydroxyvitamin D increased slightly in the sucroferric oxyhydroxide group and decreased in the sevelamer carbonate group from baseline to week 52 ( Table 2) . None of the changes in vitamin D levels were statistically significant.
Iron status
Overall change in iron parameters. The proportion of PD patients who received IV iron at least once during the 1-year treatment period was 38.6% in the sucroferric oxyhydroxide group and 31.0% in the sevelamer carbonate group. The majority of patients also received erythropoietin-stimulating agent (80.7% with sucroferric oxyhydroxide versus 72.4% with sevelamer carbonate) during the study. Defined as extension study week 28 result or the latest available measurement after extension study baseline. Week 52 is the overall endpoint value, that is, the last postbaseline, nonmissing value across both studies. c Derived by ANOVA.
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Changes in iron-related parameters in PD patients are summarized in Figure 3 . Overall increases in ferritin concentrations were observed among PD patients in the sucroferric oxyhydroxide group at week 52, whereas ferritin concentrations decreased in patients receiving sevelamer carbonate (P ¼ 0.045; Figure 3A) . Similarly, TSAT levels increased in the sucroferric oxyhydroxide group but decreased slightly in the sevelamer carbonate group after 1 year of treatment ( Figure 3B ). Hemoglobin levels remained relatively stable over 1 year in both treatment groups ( Figure 3C ). The majority of the change from baseline in a Week 24 is the week 24 result or the latest evaluable measurement after baseline (week 0) in the primary study when week 24 is missing. Week 52 is the overall endpoint value, that is, the last postbaseline, nonmissing value across both studies. P-values derived by ANOVA. serum ferritin and TSAT had occurred by week 24 in both treatment groups; changes in iron parameters were less pronounced between weeks 24 and 52.
Safety
Adverse events. The most frequent TEAEs over the 1-year study period are summarized in Table 3 . A similar proportion of PD patients reported at least one TEAE during the study in the sucroferric oxyhydroxide and sevelamer carbonate groups (86.0 and 93.1%, respectively). The incidence of treatmentrelated TEAEs was higher for sucroferric oxyhydroxide (45.6%) than sevelamer carbonate (24.1%), although the difference was not statistically significant (P ¼ 0.063). The major part of this difference was accounted for by gastrointestinal (GI) TEAEs, particularly discolored feces. The incidence of serious TEAEs was numerically higher in the sucroferric oxyhydroxide group than in the sevelamer carbonate group (36.8 versus 24.1%, respectively), although this difference was not statistically significant (P ¼ 0.331). A similar nonsignificant trend was observed with TEAEs leading to hospitalization (26.3 versus 17.2%; P ¼ 0.425). TEAEs leading to treatment discontinuation were observed in 17.5% of patients in the sucroferric oxyhydroxide group and 10.3% of patients in the sevelamer carbonate group. One patient in the sucroferric oxyhydroxide group (1.8%) experienced a TEAE related to iron overload (elevated serum ferritin level; 1038.3 ng/mL); this patient did not receive concomitant IV iron during the trial.
The proportion of PD patients who reported any GI-related TEAEs was similar in the sucroferric oxyhydroxide group (49.1%) and the sevelamer carbonate group (41.4%) (P ¼ 0.648), largely due to the higher incidence of diarrhea and discolored feces in the sucroferric oxyhydroxide group. In contrast, other GI-related TEAEs (nausea, vomiting and constipation) were reported in a higher proportion of patients receiving sevelamer carbonate. Peritonitis was reported in a similar proportion of patients treated with sucroferric oxyhydroxide and sevelamer carbonate (17.5 and 17.2%, respectively).
High variability between patients in terms of changes in serum CRP over the course of treatment was observed in the sucroferric oxyhydroxide and sevelamer carbonate groups, but levels were relatively close to baseline values by week 52 (safety set: mean change from baseline À1.1 and À1.3 mg/L, respectively).
D I S C U S S I O N
The results of this post hoc analysis demonstrate that, as reported in the overall study population, sucroferric oxyhydroxide was noninferior to sevelamer carbonate and effectively reduced serum phosphorus concentrations to within KDOQI target levels over 1 year of treatment in patients on PD. Notably, there was a significantly higher baseline serum phosphorus level in the sucroferric oxyhydroxide group.
Importantly, patients in the sucroferric oxyhydroxide group achieved a similar serum phosphorus response to those in the sevelamer carbonate group, but with a 58% lower pill burden. This finding is similar to that from the analysis of the overall study population, where the pill burden with sucroferric oxyhydroxide was 62% lower than with sevelamer carbonate [16] . The high pill burden that is associated with the use of phosphate binders is linked to low adherence and can have a deleterious impact on health-related quality of life [11, 18, 19] . Therefore, the lower pill burden associated with sucroferric oxyhydroxide in this study may have a beneficial effect on adherence to phosphate-binder treatment, particularly in realworld settings outside the controlled environment of a randomized controlled trial. Since PD patients may be seen at the clinic less frequently than HD patients, sucroferric oxyhydroxide may be a more convenient option than sevelamer carbonate for this patient population. The better compliance among sucroferric oxyhydroxide patients was particularly notable, given that 38% of patients in the sevelamer carbonate group had already been treated with the product prior to randomization, which would have been expected to favor greater compliance in the sevelamer carbonate group.
Overall, sucroferric oxyhydroxide was well tolerated in patients receiving PD and showed a similar safety profile to sevelamer carbonate. This was despite the relatively high proportion of patients in the sevelamer carbonate group that could be considered preadapted due to earlier sevelamer carbonate treatment. Although the proportion of GI-related TEAEs was slightly higher for sucroferric oxyhydroxide than for sevelamer carbonate, many of these events were attributable to diarrhea (mostly transient soft stool) and discolored feces, as would be expected with an oral iron-based product. There was a higher rate of constipation seen in patients receiving sevelamer carbonate (13.8%) compared with those receiving sucroferric oxyhydroxide (5.3%) and more diarrhea with sucroferric oxyhydroxide. Results from the Table 3 . Summary of TEAEs and specific GI-related TEAEs occurring in !5% of patients (safety set, n ¼ 86) entire dialysis population in the initial Phase 3 study and its extension showed that the incidence of these AEs generally peaked within the first few weeks of treatment and decreased over time [15, 16] . There was no difference in the rate of peritonitis between the two treatment groups.
Overall, changes in CKD-mineral and bone disorder parameters, including serum iPTH and FGF-23, among PD patients were similar to those observed in the overall study population [15, 16] . Changes in vitamin D levels among PD patients during the first 24 weeks of treatment were broadly similar to those reported for the overall study population [15] , with reductions in 25-hydroxyvitamin D in sucroferric oxyhydroxide-and sevelamer-treated patients. Serum 1,25-hydroxyvitamin D levels also decreased among PD patients in both treatment groups during the first 24 weeks of treatment; this contrasted slightly with the overall study population, where 1,25-hydroxyvitamin D concentrations decreased in the sevelamer group but remained unchanged in the sucroferric oxyhydroxide group [15] .
Initial increases in some iron-related parameters-particularly serum ferritin and TSAT-were observed in PD patients who received sucroferric oxyhydroxide. However, iron-related parameters and serum hemoglobin remained relatively stable throughout the extension study and most of the changes from baseline in these parameters had occurred by week 24. The significantly greater increase from baseline in serum ferritin (and the similar trend with TSAT) with sucroferric oxyhydroxide compared with sevelamer carbonate is likely to be due to the minimal iron absorption from sucroferric oxyhydroxide. Overall, these findings are similar to trends observed in the overall study population [15, 16, 20] .
In vitro, in vivo and early clinical studies have indicated that sucroferric oxyhydroxide is associated with low iron release [14] and absorption [21, 22] . Overall, given that iron-related parameters largely plateaued during the extension study, there appears to be minimal risk of iron accumulation or overload associated with long-term treatment with sucroferric oxyhydroxide in patients on PD. Analysis of iron parameters among patients who completed 52 weeks of treatment showed that the greatest increases in serum ferritin concentrations occurred mainly in iron-depleted patients, whereas increases in ferritin were less pronounced in patients who had higher baseline serum ferritin concentrations [20] .
This subanalysis is one of the most comprehensive comparative assessments of phosphate binders in PD patients. Although the absolute number of patients in this post hoc analysis was relatively low, it is representative of the proportions undergoing PD in the general ESRD population.
In conclusion, sucroferric oxyhydroxide offers an effective and well-tolerated treatment option, with a relatively low pill burden, compared with sevelamer carbonate for controlling serum phosphorus in patients undergoing PD.
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